Intel stock spikes after report of possible US government stake
Investing.com -- Diasorin S.p.A. shares were upgraded to “outperform” from “sector perform” by RBC Capital Markets following a period of underperformance against peers and expectations of accelerated growth from the fourth quarter of 2025, in a note dated Thursday.
The brokerage maintained its price target of €105, implying more than 25% upside from the current share price of €83.24 .
The company’s stock has fallen 17% year-to-date, while close peer bioMérieux has risen 22%.
RBC said Diasorin is trading at a valuation discount to peers that it does not consider justified, citing solid first-half results, resilience to sector headwinds, and strong mid-term growth drivers.
The stock is valued at 11 times estimated 2026 EV/EBITDA and 16 times price-to-earnings, representing discounts of 22% and 30% respectively to bioMérieux’s multiples, compared with historical average premiums of 18% and 2% .
RBC expects sales growth to accelerate in the fourth quarter, rising 9% at constant exchange rates, as headwinds subside and new product launches contribute more materially.
Growth is projected to continue into 2026 and 2027, supported by both the Immunodiagnostics and Molecular Diagnostics segments.
Immunodiagnostics is forecast to benefit from the expansion of specialty tests such as MeMed BV, LymeDetect, Calprotectin 3.0, and QuantiFeron TB.
In Molecular Diagnostics, the LIAISON PLEX multiplex platform is expected to see increased uptake around the flu season, with the potential to generate €200 million in revenues over the mid-term. The point-of-care platform LIAISON NES is scheduled for launch in 2026 .
RBC projects a 7% compound annual growth rate in sales between 2024 and 2027, with adjusted EBITDA margins rising from 33.2% in 2024 to 36.3% in 2027.
This translates into a 10% CAGR for adjusted EBITDA and 12% CAGR for adjusted earnings per share.
The brokerage pointed to the completion of investment in the Luminex integration and new platform development as factors enabling improved operating leverage .
RBC identified the full-year 2025 results and 2026 guidance, expected in March 2026, as a key catalyst, alongside several product approvals and launches in the second half of 2025 and early 2026 that could de-risk the company’s outlook.